ARTICLE | Finance
Kronos’ post-IPO gains build on $1B+ postmoney valuation
Two other biotechs also rise in aftermarket as queue swells
October 9, 2020 10:10 PM UTC
Shares of Kronos climbed 42% in their first day of trading Friday, adding to a postmoney valuation that had already topped $1 billion and leading a trio of biotechs onto NASDAQ.
At $250 million, the precision medicine company’s offering was the largest of the three, as was its first-day gain. After pricing above its proposed range at $19, Kronos Bio Inc. (NASDAQ:KRON) added $8.07 to $27.07...